Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-172 administration timing study in healthy males
NCT07084961Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TS-172 in hyperphosphatemia (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Urinary excretion of phosphorus and Urinary excretion of sodium. Started Aug 2025; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT07084961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084961.